Gopal Sarker, MD
Hospitalist · Springfield, MANPI 1316929607
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 158 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 22 manufacturers reported payments, led by AbbVie at 32.0% of the total. Reporting peaked in 2020 at $580 and has fallen 71.2% since, to $167 in 2025. Among hospitalist clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 158 payments — averaging $14.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$752
- GSK$459
- Novo Nordisk$331
- Lilly USA, LLC$91
- Scilex Pharmaceuticals Inc.$86
- Pfizer$69
- plus $559 from 16 others
What the payments were for
- Food & beverage$2,347100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 53 | $752 |
| GSK | 42 | $459 |
| Novo Nordisk | 17 | $331 |
| Lilly USA, LLC | 5 | $91 |
| Scilex Pharmaceuticals Inc. | 5 | $86 |
| Pfizer | 4 | $69 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $62 |
| AstraZeneca | 4 | $62 |
| Amarin Pharma, Inc. | 3 | $50 |
| Johnson & Johnson | 3 | $49 |
| Abbott | 2 | $40 |
| Novartis | 2 | $38 |
| Boehringer Ingelheim | 2 | $38 |
| Genentech USA, Inc. | 2 | $31 |
| Merck | 2 | $30 |
| Ironwood Pharmaceuticals, Inc | 2 | $29 |
| Kowa Pharmaceuticals America, Inc. | 2 | $27 |
| Astellas Pharma US Inc | 1 | $27 |
| Amgen | 1 | $24 |
| Phathom Pharmaceuticals, Inc. | 1 | $21 |
| E.r. Squibb & Sons, L.L.C. | 1 | $20 |
| Bausch Health US, LLC | 1 | $11 |
How this compares
$2,347 in reported general payments places this provider in the 95th percentile of 599 hospitalist providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 77 | $100,089 |
| JanuviaSitagliptin Phosphate | 44 | $51,250 |
| EliquisApixaban | 49 | $36,258 |
| FarxigaDapagliflozin Propanediol | 35 | $36,002 |
| JardianceEmpagliflozin | 16 | $20,398 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 23 | $18,612 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 19 | $13,695 |
| JanumetSitagliptin Phos/Metformin Hcl | 13 | $12,553 |
| Atorvastatin Calcium | 425 | $3,755 |
| Omeprazole | 132 | $2,339 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 75 | $1,825 |
| Metoprolol Succinate | 107 | $1,765 |
| Rosuvastatin Calcium | 111 | $1,683 |
| Methylphenidate ErMethylphenidate Hcl | 12 | $1,399 |
| Esomeprazole Magnesium | 18 | $1,257 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $331 | $100,08977 claims |
| MerckJanuvia, Janumet Xr, Janumet | $30 | $77,49976 claims |
| PfizerEliquis | $69 | $36,25849 claims |
| AstraZenecaFarxiga | $62 | $36,00235 claims |
| Boehringer IngelheimJardiance | $38 | $20,39816 claims |
| GSKTrelegy Ellipta | $459 | $18,61223 claims |
| AbbVieSynthroid | $752 | $48813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 599 hospitalist providers in Massachusetts.
Other hospitalist in Springfield
- Jishu MottaSpringfield$36K
- Sohail WaienSpringfield$6K
- Jeyavarna KarthikeyanSpringfield$423
- Sahil KheraBurlington$226K
- Jane MeiselBoston$83K
- Joongheum ParkBoston$64K
- Shreya TrivediBoston$20K
- Aarti GroverBoston$4K
- Leticia HelmsBoston$4K
- Rachel GoodmanBoston$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.